- HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively
- As previously announced, Phase 3 development in chronic hepatitis B to occur only with a global development and commercialization partner, which has not been secured
- Vir Biotechnology to streamline the final stages of MARCH Phase 2 study to ensure continued participant benefit and safety, while applying continued financial stewardship
- The Company reiterates cash runway guidance into mid-2027, based on the current operating plan
- The Company remains committed to its chronic hepatitis delta program, based on the transformational potential of tobevibart + elebsiran to achieve complete hepatitis delta viral suppression in a majority of patients
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 21% (3/14) of participants with baseline HBsAg